Stocks and Investing Stocks and Investing
Tue, February 28, 2023

Gregory Renza Maintained (ACAD) at Buy with Increased Target to $27 on, Feb 28th, 2023


Published on 2024-10-28 01:57:36 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $19 to $27 on, Feb 28th, 2023.

Gregory has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $17 on, Wednesday, February 15th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
  • Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Gregory


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
Contributing Sources